Invea-Therapeutics-Logo-Final

Our Pipeline

Precision medicines for debilitating disorders with a high unmet need
Invea has identified and prioritized a pipeline of three candidates impacting the GBA for the treatment of GI and hepatobiliary disorders. Our discovery pipeline has more than 20 programs at various stages of validation.

INVA8001

INVA8001 is a first-in-class, oral, highly selective inhibitor of chymase impacting inflammation, tissue remodeling, and fibrosis, with proven human safety, for the treatment of Eosinophilic Gastritis/Duodenitis (EG/EoD), Eosinophilic Esophagitis (EoE), and Primary Sclerosing/Biliary Cholangitis.

INVA8002

INVA8002 is a novel orally delivered colon-targeted formulation of a small molecule inhibitor of a 5-HT3 receptor for the treatment of moderate to severe Ulcerative Colitis (UC), a common form of Inflammatory Bowel Disease (IBD).

INVA8003

INVA8003 is a first-in-class pan- inflammasome inhibitor targeting ASC protein oligomerization, which disrupts the inflammasome assembly of NLR/Ps with a broad anti-inflammatory impact and potential applications across a wide range of inflammatory GI disorders.